Mobilization Strategies in Myeloma Patients Intended for Autologous Hematopoietic Cell Transplantation
Transfusion Medicine and Hemotherapy · 2023 · 50 (5) · 438-447
DOI: 10.1159/000531940 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Transfusion Medicine and Hemotherapy, online erschienen am 24.08.2023. Verfasst von Esa Jantunen und 4 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Clinical Medicine/Internal Medicine, University of Eastern Finland, Kuopio, Finland. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 101 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Themen: Mobilisation
Abstract (Originalsprache)
Background: Multiple myeloma is currently the leading indication for autologous hematopoietic cell transplantation (AHCT). A prerequisite for AHCT is mobilization and collection of adequate blood graft to support high-dose therapy. Current mobilization strategies include granulocyte colony-stimulating factor (G-CSF) alone or in combination with chemotherapy most commonly cyclophosphamide (CY). More recently, plerixafor has become into agenda especially in patients who mobilize poorly. In the selection of a mobilization method, several factors should be considered. Summary: Preplanned collection target is important as G-CSF plus plerixafor is more effective in the mobilization of CD34+ cells than G-CSF alone. On the other hand, CY plus G-CSF is superior to G-CSF only mobilization. Previous therapy and age of the patients are important considerations as G-CSF alone may not be effective enough in patients with risk factors for poor mobilization. These factors include extensive lenalidomide exposure, irradiation to bone marrow-bearing sites, higher age, or a previous mobilization failure. Also, local preferences and experiences as well as the number of apheresis needed are important issues as well as cost-effectiveness considerations. Mobilization method used may have implication for cellular composition of collected grafts, which might have an impact on posttransplant events such as hematologic and immune recovery in addition to also potential long-term outcomes. Key Message: Currently, G-CSF alone and preemptive plerixafor if needed might be considered as a standard mobilization strategy in MM patients intended for AHCT.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institute of Clinical Medicine/Internal Medicine, University of Eastern Finland, Kuopio, Finland.
- Department of Medicine, Kuopio University Hospital, Kuopio, Finland.
- Department of Medicine, Kymenlaakso Central Hospital, Kotka, Finland.
- Department of Hematology, Comprehensive Cancer Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.
Zitieren
APA
Jantunen, E., Partanen, A., Turunen, A., Varmavuo, V., & Silvennoinen, R. (2023). Mobilization Strategies in Myeloma Patients Intended for Autologous Hematopoietic Cell Transplantation. Transfusion Medicine and Hemotherapy, 50(5), 438-447. https://doi.org/10.1159/000531940
Vancouver
Jantunen E, Partanen A, Turunen A, Varmavuo V, Silvennoinen R. Mobilization Strategies in Myeloma Patients Intended for Autologous Hematopoietic Cell Transplantation. Transfusion Medicine and Hemotherapy. 2023;50(5):438-447. doi:10.1159/000531940
BibTeX
@article{Jantunen2023,
author = {Jantunen, Esa and Partanen, Anu and Turunen, Antti and Varmavuo, Ville and Silvennoinen, Raija},
title = {Mobilization Strategies in Myeloma Patients Intended for Autologous Hematopoietic Cell Transplantation},
journal = {Transfusion Medicine and Hemotherapy},
year = {2023},
volume = {50},
number = {5},
pages = {438--447},
doi = {10.1159/000531940}
}
EUVIMED